![]() Youssef suggested people talk to their doctor to make sure it is the right vaccine delivery system for them. ![]() It’s going to be more of a data about the tolerability and how good of a response the host amounts to.”Īs intranasal COVID-19 vaccines become more readily available, Dr. So the mode of administration and of itself should not be held against or for the vaccine. Some influenza vaccines are given intranasally and they work pretty well. “We’ve used nasal vaccines for other diseases. “I think it’s great to have different options for patients that they can choose from, whatever they’re most comfortable with,” he stated. Fady Youssef, a board-certified pulmonologist, internist, and critical care specialist at MemorialCare Long Beach Medical Center in Long Beach, CA, about these new intranasal vaccines and what benefits they might offer. What benefits might intranasal vaccines offer? The intranasal vaccine reportedly showed “successful results” following phase 1, 2, and 3 clinical trials. The phase 3 clinical trial results for Convidecia showed a 57.5% efficacy rate against SARS-CoV-2 infection preventing symptomatic COVID-19 28 days or more after vaccination.īharat Biotech’s iNCOVACC nasal vaccine was developed in partnership with Washington University St. Researchers have also conducted studies on using adenovirus vectors as a vaccine platform for other diseases, including HIV-1, Ebola, and various other infectious diseases.Īccording to statements on CanSino Biologics website, Convidecia Air uses the same adenovirus vector technological platform as Convidecia, the company’s injectable COVID-19 vaccine.Ĭonvidecia recently received emergency use listing from the World Health Organization (WHO). Adenoviral vectors are genetically engineered viruses previously used in gene therapy. When the vaccine enters the body, the protein attaches to cells in the body, teaching them to trigger an immune response if they ever encounter that same protein again.īoth of these intranasal vaccines also use adenovirus vector technology. That means they use a protein from the SARS-CoV-2 virus in the vaccine. And 1 out of every 10 people may put off having the COVID-19 vaccination due to their fear of needles.īoth Convidecia Air from CanSino Biologics, and iNCOVACC from Bharat Biotech International Limited are recombinant vaccines. Experts estimate that 1 out of 4 adults and 2 out of 3 children are afraid of shots. And because the nose connects to the body’s respiratory system, this makes it easy for a nasal vaccine to move through the body.Īdditionally, nasal vaccines provide less stress for people who are afraid of needles. The mucosa also absorbs certain pathogens. ![]() When a person breathes, the mucosa helps keep bacteria and other potentially problematic particles from getting into their body. The mucosa is an important part of the body’s immune system. The glands in the mucosa are what produce mucus. The mucosa, or mucus membrane, is the moist inner layer of body cavities, such as the nose and mouth, as well as some organs. Some researchers believe that delivering a vaccine nasally provides the benefit of administering the vaccine directly into the mucosa of the body. There have also been studies conducted on nasal vaccines for other diseases, including pertussis (whooping cough), hepatitis B, and the African swine fever virus. The most widely known nasal vaccines right now are for influenza, commonly known as the flu. ![]() However, this is not the first time scientists have developed an intranasal vaccine option. The most common way of administering a vaccine continues to be through an injection. Now, two companies are planning to change that through the development of COVID-19 vaccines inhaled through the nose.ĬanSino Biologics, a Chinese pharmaceutical company, recently received approval from the National Medical Products Administration of China for Convidecia Air, their recombinant vaccine delivered via inhalation, as a nasal spray.īharat Biotech International, a biotechnology company headquartered in India, has been granted approval under Restricted Use in Emergency Situation in India for its iNCOVACC recombinant vaccine administered intranasally as nasal drops. Up to now, all approved COVID-19 vaccines have been subcutaneous - that is, administered under the skin, often by injection into the upper area of the arm. Visit our coronavirus hub for the most recent information on the COVID-19 pandemic.Īs the COVID-19 pandemic continues, new vaccines to prevent infection with SARS-CoV-2, the virus that causes COVID-19m are under constant development. All data and statistics are based on publicly available data at the time of publication. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |